CiTSA

CiTSA provides experimentally supported immunotherapy signatures and analytical resources to characterize molecular and cellular determinants of cancer immunotherapy response.

Key Features:

• Benchmarking Dataset: A curated dataset of 878 experimentally supported associations between signatures (such as genes and cells) and immunotherapies across 30 cancer types derived from published literature.
• Identification and Visualization: Identification and visualization of molecular and cellular features and their interactions.
• Functional Analysis: Functional analysis to explore the roles of different signatures in cancer immunotherapy.
• Correlation and Survival Analysis: Correlation studies and survival analyses to assess prognostic implications of specific signatures.
• Single-cell and Bulk Data Analysis: Analysis of scRNA-seq and bulk datasets including cell clustering, cluster activity assessment, and cell-cell communication analysis.

Scientific Applications:

• Mechanistic Insights: Elucidating how molecular and cellular features interact with immunotherapies to inform mechanisms of response and resistance.
• Therapeutic Target Development: Identifying signature associations across cancer types to support discovery of novel therapeutic targets.
• Precision Immunotherapy: Enabling analysis of patient-specific signatures to inform personalized immunotherapy strategies.

Methodology:

Curated extraction of 878 experimentally supported signature–immunotherapy associations from published literature; computational methods explicitly include identification and visualization, functional analysis, correlation and survival analysis, cell clustering, cluster activity assessment, and cell–cell communication analysis on scRNA-seq and bulk datasets.